Evenity (Romosozumab) Safety in Adults 65 and Older

The Cardiovascular Safety Signal: What the Trials Show

The primary safety concern for geriatric patients receiving romosozumab is the cardiovascular risk identified in the ARCH trial. In this active-comparator study of 4,093 postmenopausal women (median age 74), positively adjudicated MACE events occurred in 50 patients (2.5%) in the romosozumab group vs. 38 (1.9%) in the alendronate group during the 12-month romosozumab treatment period.

This signal drove the FDA to require a boxed warning stating that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. The warning specifically contraindicates use in patients who have had a myocardial infarction or stroke within the preceding year.

The absolute risk difference was 0.6 percentage points. That number sounds small, but the geriatric population accumulates cardiovascular risk factors at a rate that makes even modest signal amplification clinically meaningful. Patients aged 75+ in the ARCH trial had higher event rates in both arms compared to those 65-74, though subgroup analyses were not powered for statistical significance [1].

By contrast, the FRAME trial (N=7,180, median age 71) used a placebo comparator and did not detect a MACE imbalance: 0.8% romosozumab vs. 0.8% placebo at 12 months [2]. The divergence between trials may reflect the older, sicker ARCH population or differences in comparator effects. Some investigators have hypothesized that alendronate confers modest cardiovascular protection, making romosozumab appear comparatively worse.

Renal Function and Dose Considerations in Older Adults

No dose adjustment is recommended for patients with mild-to-moderate renal impairment (eGFR 30-89 mL/min/1.73m²), per the FDA prescribing information. The 210 mg monthly dose remains fixed regardless of weight or renal status.

The problem arises below that threshold. Patients with eGFR <30 were excluded from the key trials, so safety data in advanced CKD (stages 4-5) is extremely limited. Given that approximately 38% of adults over age 75 have CKD stage 3 or higher according to CDC epidemiologic data, this gap affects a substantial proportion of the target population [3].

Romosozumab is a monoclonal antibody cleared by proteolytic degradation, not renal excretion. Theoretically, kidney function should not alter drug levels. The concern is pharmacodynamic: patients with CKD have disordered calcium and phosphate metabolism, secondary hyperparathyroidism, and adynamic bone disease. These conditions alter the substrate on which romosozumab acts.

The Endocrine Society 2020 guidelines recommend checking serum calcium, 25-hydroxyvitamin D, and PTH before initiating romosozumab, with particular vigilance in patients with eGFR <45. Hypocalcemia has been reported post-marketing, predominantly in patients with pre-existing vitamin D deficiency or advanced CKD [4].

Hypocalcemia Risk: Higher Stakes After 65

Romosozumab suppresses sclerostin, releasing the brake on osteoblast-mediated bone formation. Rapid new bone mineralization draws calcium from the circulation. In young, vitamin D-replete patients, compensatory PTH secretion and intestinal calcium absorption prevent symptomatic hypocalcemia. Geriatric patients often lack this reserve.

Risk factors concentrated in the 65+ population include vitamin D deficiency (present in an estimated 40-50% of community-dwelling older adults per NIH data), reduced dietary calcium intake, impaired intestinal absorption, and blunted PTH response in CKD [5]. Concurrent use of loop diuretics, common in heart failure management, further increases urinary calcium losses.

The prescribing information recommends calcium and vitamin D supplementation during treatment but does not specify a target 25(OH)D level. Most bone metabolism experts target 30-50 ng/mL before initiation [6]. Checking serum calcium at 2-4 weeks after the first injection is reasonable in high-risk geriatric patients, though no formal monitoring protocol exists in the label.

Falls, Fractures, and the Benefit-Risk Calculus

The reason clinicians accept cardiovascular uncertainty is the magnitude of fracture reduction. Falls are the leading cause of injury death in adults 65+ according to CDC injury statistics, and hip fractures carry 20-30% one-year mortality in patients over 80 [7].

In ARCH, romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months (including the 12-month transition period to alendronate in the romosozumab arm) [1]. Hip fracture risk was reduced by 38% over the same timeframe. These are reductions against an active comparator already proven to reduce fractures.

The FRAME trial demonstrated a 73% relative risk reduction in new vertebral fractures vs. placebo at 12 months (0.5% vs. 1.8%, P<0.001) [2]. Non-vertebral fracture reduction reached statistical significance only after the transition to denosumab in year two.

For a 78-year-old woman with a T-score of -3.2 and a prior vertebral fracture, the absolute fracture risk reduction over 12 months likely exceeds the absolute cardiovascular risk increase. The calculation shifts unfavorably if that same patient has a history of transient ischemic attack or established coronary artery disease.

Cardiovascular Screening Before Initiation

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend assessing cardiovascular risk before prescribing romosozumab. No validated screening tool has been formally endorsed for this specific decision, but the following approach reflects consensus practice [8]:

Review the patient's history for MI, stroke, TIA, peripheral arterial disease, or coronary revascularization. Any event within the prior 12 months is a contraindication per the boxed warning. Events beyond 12 months require individualized risk-benefit discussion.

Assess modifiable cardiovascular risk factors: uncontrolled hypertension (systolic >160 mmHg), active smoking, HbA1c >9%, LDL >190 mg/dL without treatment. These do not individually contraindicate romosozumab, but their accumulation may tip the risk-benefit calculation toward alternative agents like denosumab or teriparatide.

A 10-year ASCVD risk score >20% (high risk per ACC/AHA guidelines) warrants serious consideration of alternatives, though this threshold is not codified in any bone-specific guideline [9].

Drug Interactions Relevant to Geriatric Polypharmacy

Romosozumab has no known cytochrome P450 interactions or transporter-mediated drug-drug interactions. As a monoclonal antibody, it is degraded by intracellular proteolysis, not hepatic metabolism. This pharmacokinetic simplicity is an advantage in the polypharmacy environment typical of patients 65+.

The relevant interactions are pharmacodynamic. Concurrent calcium channel blockers and loop diuretics affect calcium homeostasis. Anticoagulants (warfarin, DOACs) increase bleeding risk at injection sites, though clinically significant hematomas are rare. Chronic corticosteroid use (>5 mg prednisone equivalent daily) accelerates bone loss and may blunt the anabolic response, though no formal interaction study has been conducted [10].

One clinically important consideration: patients transitioning from denosumab to romosozumab (an uncommon sequence, but occasionally attempted) face rebound bone loss risk if denosumab is discontinued without adequate bisphosphonate bridging. The 2022 position statement from the American Society for Bone and Mineral Research explicitly warns against denosumab discontinuation without antiresorptive transition [11].

Sequential Therapy: What Comes After 12 Doses

Romosozumab is approved only for 12 monthly doses. Bone mineral density gains achieved during treatment begin to reverse within months of completion unless an antiresorptive agent follows. This makes the post-romosozumab transition a safety-critical step for geriatric patients.

The ARCH trial protocol transitioned patients to alendronate 70 mg weekly. The FRAME trial used denosumab 60 mg every 6 months. Both sequences maintained or further improved BMD gains through year two [1][2].

For geriatric patients, denosumab is often preferred as the follow-on agent because it does not require the upright positioning and esophageal transit time that oral bisphosphonates demand. Pill burden and gastrointestinal tolerability are genuine barriers in patients 75+ who may have esophageal dysmotility, cognitive impairment affecting medication adherence, or difficulty maintaining the 30-minute upright posture.

Zoledronic acid (5 mg IV annually) offers another option that eliminates adherence concerns entirely. A single infusion 1-2 months after the final romosozumab dose provides antiresorptive coverage for 12 months [12]. For patients with eGFR <35, zoledronic acid is contraindicated, and denosumab becomes the default.

Injection-Site Reactions and Practical Administration

Each monthly dose requires two subcutaneous injections (105 mg each) administered consecutively in the abdomen, thigh, or upper arm. The dual-injection format is unique among osteoporosis therapies and can present challenges for geriatric patients.

In FRAME, injection-site reactions (pain, erythema, pruritus) occurred in 5.2% of romosozumab patients vs. 2.9% placebo [2]. Reactions were generally mild and did not lead to treatment discontinuation in most cases.

Practical considerations for the 65+ population: thin subcutaneous tissue may increase injection discomfort; anticoagulated patients may develop bruising; patients with limited mobility may need clinic-based administration rather than home self-injection. The prefilled syringes require refrigeration and 30-minute room-temperature equilibration before use.

Arthralgia was reported in 12.4% of romosozumab patients in FRAME vs. 10.6% placebo [2]. This modest excess is difficult to distinguish from background musculoskeletal complaints in an elderly population with high prevalence of osteoarthritis.

Monitoring Protocol for Geriatric Patients on Romosozumab

No mandatory monitoring schedule exists in the FDA label beyond pre-treatment assessment. A reasonable evidence-informed protocol for patients 65+ includes the following checkpoints:

Before first dose: serum calcium, 25(OH)D, PTH, comprehensive metabolic panel (including creatinine/eGFR), and DEXA within the prior 24 months. Document cardiovascular history and current ASCVD risk [4][8].

After dose 1 (2-4 weeks): serum calcium in patients with eGFR <45, vitamin D deficiency, or malabsorption syndromes. Not required in low-risk patients.

Month 6: clinical assessment for new symptoms (chest pain, neurologic deficits, injection-site concerns). No routine labs required unless clinically indicated.

After dose 12 (within 1 month): plan and initiate sequential antiresorptive therapy. Repeat DEXA at 12-15 months from romosozumab initiation to document response. Expected lumbar spine BMD gain is 13-15% at 12 months based on FRAME data [2].

Post-treatment year 1: confirm antiresorptive adherence, repeat DEXA at 24 months, reassess fracture risk and need for continued antiresorptive therapy.

When to Choose an Alternative Agent

Romosozumab is not the default first-line therapy for every geriatric patient with osteoporosis. The NOF/AACE treatment algorithm positions it for very high fracture risk: T-score ≤ -3.0, prior vertebral or hip fracture, or FRAX-calculated 10-year hip fracture probability >3% [8].

Prefer denosumab or zoledronic acid over romosozumab when: (1) the patient has had an MI, stroke, or TIA within 12 months (absolute contraindication); (2) 10-year ASCVD risk exceeds 20% and fracture risk is moderate rather than very high; (3) the patient cannot reliably attend monthly clinic visits for 12 consecutive months; (4) cost is prohibitive and the patient lacks insurance coverage (wholesale acquisition cost approximately $1,825/month).

Prefer teriparatide (Forteo) or abaloparatide (Tymlos) when: (1) the patient has cardiovascular contraindications to romosozumab but qualifies for anabolic therapy; (2) prior radiation therapy to the skeleton (though both PTH analogs carry osteosarcoma precautions in animal models); (3) glucocorticoid-induced osteoporosis where teriparatide has specific trial evidence from the Saag et al. NEJM 2007 study [13].

Romosozumab produces greater BMD gains at the spine than teriparatide (13.3% vs. 7.1% at 12 months in the STRUCTURE trial), which may favor romosozumab in patients with severe vertebral osteoporosis and acceptable cardiovascular risk [14].